This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Advancing today’s therapies to enable healthier lives
Our innovative proprietary technology platform, Arestat™ enables us to develop future medicines from existing therapies, across all disease indications and at any stage of a drug lifecycle
Using our Arestat™ technology platform, we are developing enhanced medicines for diabetes and other indications through our proprietary pipeline and in partnership with leading pharmaceutical and biotechnology companies
Our Products
Our potential products for diabetes and for specialist hospital use are designed to improve patient outcomes and enable healthier lives
Our Partners
We work with many of the top 20 leading pharmaceutical companies to enhance product formats, find solutions to development challenges and create differentiated products offering the potential for significant improvements in patient safety and convenience
Latest News and Events
-
20th September 2021
ARECOR ANNOUNCES POSITIVE HEADLINE RESULTS FROM FIRST PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN CANDIDATE FOR DIABETES
-
9th September 2021
FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR AT247, AN ULTRA-RAPID INSULIN FOR THE TREATMENT OF DIABETES
-
7th September 2021
EXCLUSIVE FORMULATION COLLABORATION WITH INTAS PHARMACEUTICALS LTD